Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1984 July; 50(1): 45–49.
PMCID: PMC1976928

Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.


Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The dose of acyclovir was 200 mg four times daily for the duration of chemotherapy (six weeks). Of the 40 evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P less than 0.001), and the incidence of viral isolates from 70% on placebo to 5% on acyclovir (P less than 0.001).

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (645K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aston DL, Cohen A, Spindler MA. Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders. Br Med J. 1972 Nov 25;4(5838):462–465. [PMC free article] [PubMed]
  • Blackledge G, Bush H, Chang J, Crowther D, Deakin DP, Dodge OG, Garrett JV, Palmer M, Pearson D, Scarffe JH, et al. Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group). Eur J Cancer. 1980 Nov;16(11):1459–1468. [PubMed]
  • Nealon TF, Jr, Sugerman H, Shea W, Fleegler E. An extracorporeal device to treat barbiturate poisoning. Use of anion-exchange resins in dogs. JAMA. 1966 Jul 11;197(2):118–120. [PubMed]
  • Chou S, Gallagher JG, Merigan TC. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet. 1981 Jun 27;1(8235):1392–1394. [PubMed]
  • Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, Nebout T, Mazeron MC, Perol Y. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983 Sep 24;2(8352):706–708. [PubMed]
  • Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE, Burke C, Crawford DH, Brumfitt W, Hoffbrand AV. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):384–388. [PMC free article] [PubMed]
  • Lam MT, Pazin GJ, Armstrong JA, Ho M. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study. Cancer. 1981 Nov 15;48(10):2168–2171. [PubMed]
  • Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 1980 Sep;142(3):338–346. [PubMed]
  • Mitchell CD, Bean B, Gentry SR, Groth KE, Boen JR, Balfour HH., Jr Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet. 1981 Jun 27;1(8235):1389–1392. [PubMed]
  • Muller SA, Herrmann EC, Jr, Winkelmann RK. Herpes simplex infections in hematologic malignancies. Am J Med. 1972 Jan;52(1):102–114. [PubMed]
  • Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. [PubMed]
  • Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. [PubMed]
  • Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med. 1982 Mar;96(3):265–269. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK